Holen Sie sich die Stockscreener-App
52.87
0.51%
0.27
Handel nachbörslich:
52.29
-0.58
-1.10%
Metsera Inc Aktie (MTSR) Neueste Nachrichten
Metsera (MTSR): Evaluating Valuation After a 48% One-Month Share Price Surge - Yahoo Finance
Metsera (NASDAQ:MTSR) Receives Sell (D) Rating from Weiss Ratings - MarketBeat
Metsera Inc. stock trend forecastJuly 2025 Action & Smart Allocation Stock Tips - newser.com
How to integrate Metsera Inc. into portfolio analysis toolsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Pfizer Aims To Close Gap On Obesity Drugs With Metsera 09/23/2025 - MediaPost
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders - The Malaysian Reserve
Novo Nordisk’s liver deal misses bigger ailment - Reuters
What data driven models say about Metsera Inc.’s futureJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Does Metsera Inc. show high probability of reboundSwing Trade & Accurate Intraday Trading Signals - newser.com
Is Metsera Inc. stock near bottom after declineJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
Will Metsera Inc. rebound enough to break even2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
Applying Elliott Wave Theory to Metsera Inc.Weekly Stock Analysis & Technical Pattern Based Signals - newser.com
Pfizer: Mastering The Art Of The Deal With MetseraUpgraded To Buy (NYSE:PFE) - Seeking Alpha
Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Down 50%, Should You Buy the Dip on Pfizer? - The Motley Fool
Is this a good reentry point in Metsera Inc.Exit Point & Consistent Return Investment Signals - newser.com
Is Metsera Inc. stock poised for growthWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Will earnings trigger a reversal in Metsera Inc.July 2025 PostEarnings & Verified Trade Idea Suggestions - newser.com
Is Metsera Inc. stock resilient to inflationJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles - MSN
Where Metsera’s data fit in the obesity landscape - BioCentury
Will Metsera Inc. stock split again soonWeekly Market Report & Expert Curated Trade Setup Alerts - newser.com
Metsera (NASDAQ:MTSR) Raised to "Hold" at Wall Street Zen - MarketBeat
Metsera’s Phase IIb GLP-1 Data Show Competitive Efficacy, Tolerability - insights.citeline.com
Metsera strengthens case for Pfizer buyout with latest study data - BioPharma Dive
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial - inkl
PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 b - The Economic Times
PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisition - MSN
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer. - Barron's
Pfizer M&A prospect Metsera heads to phase III with lead GLP-1 - BioWorld MedTech
Trump’s MFN deadline came and went - statnews.com
Metsera’s Obesity Drug Shows 'Very Encouraging' Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet - BioSpace
Metsera (NASDAQ:MTSR) Cut to Equal Weight at Wells Fargo & Company - MarketBeat
Pfizer licking its lips as Metsera presents positive weight loss data - The Pharma Letter
Wells Fargo Downgrades Metsera to Equal Weight From Overweight, Cuts Price Target to $54 From $65 - MarketScreener
Metsera’s new obesity data mean Pfizer has side effect and efficacy questions to answer - Endpoints News
Pfizer's new prize Metsera touts 14% weight loss, 'class-leading tolerability' for lead GLP-1 drug - Fierce Biotech
Pfizer Acquires Metsera to Re-Enter Obesity Drug Arena - PharmiWeb.com
Pfizer-bound Metsera touts Phase II double-header for GLP-1 hopeful - FirstWord Pharma
Metsera’s weight loss drug shows 14.1% reduction in phase 2b trials - Investing.com Nigeria
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):